SynthesisPloS one2021
Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.Frontiers in immunology · 2022Pooled it
- TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.Future oncology (London, England) · 2026Trial
- Clinical characteristics and treatment patterns of tenosynovial giant cell tumor in Japan: an analysis of the Japanese bone and soft tissue tumor registry.International journal of clinical oncology · 2026Article
- Predictors of Recurrence in Hand Giant Cell Tumor of Tendon Sheath: A Systematic Review.Plastic and reconstructive surgery. Global open · 2026Article
- Expression of Molecular Markers Associated with Tenosynovial Giant Cell Tumours and Bone Destruction: A Systematic Review.Journal of clinical medicine · 2026Review
- Multifocal tenosynovial giant cell tumor: A case report.Radiology case reports · 2026Article
- A unique coincidence: Concurrent oncocytic thyroid Carcinoma and tenosynovial giant cell tumor: A case report.Asia Oceania journal of nuclear medicine & biology · 2026Article
- Tenosynovial giant cell tumor and its differential diagnosis in children.Pediatric radiology · 2025Review
- Tenosynovial Giant Cell Tumors in the Hand and Foot.Cureus · 2025Article
- Microsurgical resection of tenosynovial giant cell tumor in the digits microsurgery for digital GCT.Journal of hand and microsurgery · 2025Article
- Tenosynovial giant cell tumours of the foot and ankle: a retrospective single centre experience with surgical treatment of 34 cases.BMC cancer · 2025Article
- Multiportal Arthroscopy-assisted Surgical Resection of Diffuse-type Tenosynovial Giant Cell Tumors in the Ankle Joint Yields Favorable Clinical Outcomes: A Retrospective Study.Orthopaedic surgery · 2024Article
- Endoscopic En Bloc Resection of Giant Cell Tumor of Tendon Sheath of Anterior Ankle.Arthroscopy techniques · 2024Article
- Multiple extraarticular giant cell tumors.JAAD case reports · 2024Article
- Article
- Giant Cell Tumor of the Tendon Sheath of the Hand: Analysis of Factors Impacting Recurrence.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2024Article
- Invasion Patterns and Long-Term Clinical Outcomes of Diffuse Tenosynovial Giant Cell Tumor of the Ankle Joint.Cureus · 2024Article
- Article
- Insights into the Distribution Patterns of Foot and Ankle Tumours: Update on the Perspective of a University Tumour Institute.Journal of clinical medicine · 2024Article
- Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor.Case reports in orthopedics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tenosynovial giant cell tumor (TGCT) is a usually benign lesion which arises from the synovium. It affects joints, tendon sheaths and bursae. The clinical course is often unpredictable, and local recurrences frequently occur. The aim of this study was to describe different treatment options, surgical complications, and to develop a follow-up regime based on a systematic literature review and meta-analysis of foot and ankle lesions. METHODS AND
results1284 studies published between 01/1966 and 06/2021 were identified. 25 met the inclusion criteria, with a total of 382 patients. Of these, 212 patients had a diffuse (dTGCT) and 170 a localized (lTGCT) TGCT. Patients with a dTGCT had a mean age of 36.6±8.2 years, and 55% were female. The overall complication rate was 24% in dTGCT, irrespective of the therapeutic procedure; the mean follow-up was 37.9±27.4 months with a recurrence rate of 21%, and recurrences occurred between 3 and 144 months, the vast majority (86%) within the first 5 years following intervention. Patients with a lTGCT had a mean age of 31.2±5.7 years, and 53% were female. Complications occurred in 12%. The mean follow-up was 51.1±24.6 months, the recurrence rate was 7%, and recurrence occurred between 1 and 244 months after intervention.
conclusionDiffuse TGCTs of the foot and ankle region have a remarkable recurrence rate irrespective of therapeutic procedures, and most lesions reoccurred within 5, with more than half of these in the first 2 years. The lTGCTs are well treatable lesions, with a low recurrence and a moderate complication rate. Based on these findings, we propose a follow-up regime for the dTGCT including a clinical survey and MR imaging 3 months after surgical intervention (baseline), followed by twice-yearly intervals for the first 2 years, yearly intervals up to the fifth year, and further individual follow-up due to the fact that recurrences can even occur for years later. For the lTGCT a clinical survey and MRT is proposed after 3-6 months after intervention (baseline), followed by annual clinical examination for 3 years, and in case of symptoms MR-imaging. Larger prospective multi-center studies are necessary to confirm these results and recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.